THE STUDY OF RENOPROTECTIVE PROPERTIES OF ERYTROPOETIN DERIVATIVES ON THE KIDNEY ISCHEMIA-REPERFUSION MODEL

Aim. The research was designed to study the renoprotective properties of erythropoietin derivatives on the kidney ischemiareperfusion experimental model.

Materials and methods. The renoprotective properties of asialo erythropoietin (0.4 μg/kg and 2.4 μg/kg 30 minutes before the induction of ischemia) and carbamylated darbepoetin (50 μg/kg 24 hours before the ischemic stimulus) were studied in comparison with erythropoietin and darbepoetin in a series of experiments on male Wistar rats on a 40-minute bilateral model of renal ischemia-reperfusion. The renoprotective properties were evaluated by the results of biochemical markers of acute kidney injury, the dynamics of glomerular filtration rate and fractional sodium excretion, as well as the severity of microcirculatory disorders.

Results. It was found that the prophylactic use of asialo erythropoietin (dose-dependent) and carbamylated darbepoetin leads to a decrease in the serum concentration of markers of acute renal damage, an increase in the glomerular filtration rate, a decrease in fractional sodium excretion, and a decrease in microcirculatory disorders.

Conclusion. Asialo erythropoietin and carbamylated darbepoetin have the pronounced renoprotective properties and are the promising agents for the prevention and treatment of acute kidney injury.

1. Chatauret N., Badet L., Barrou B., Hauet T. Ischemiareperfusion: from cell biology to acute kidney injury. Prog Urol. 2014; 24(Suppl 1): 4-12.

2. Hammad F.T., Lubbad L. The effect of thymoquinone on the renal functions following ischemia-reperfusion injury in the rat. International Journal of Physiology, Pathophysiology and Pharmacology. 2016; 8(4): 152-159.

3. Mao H., Katz N., Ariyanon W., Blanca-Martos L., Adýbelli Z., Giuliani A., Danesi T.H., Kim J.C., Nayak A., Neri M., Virzi G.M., Brocca A., Scalzotto E., Salvador L., Ronco C. Cardiac surgery-associated acute kidney injury. Cardiorenal Medicine. 2013; 3(3): 178-199. DOI:10.1159/000353134.

4. Legrand M., Mik E.G., Johannes T., Payen D., Ince C. Renal hypoxia and dysoxia after reperfusion of the ischemic kidney. Mol Med. 2008; 14(7-8): 502-516.

5. Hussien N.I., Emam H.T. The potential protective effects of erythropoietin and estrogen on renal ischemia reperfusion injury in ovariectomized rats. Alexandria Journal of Medicine. 2016; 52(4): 325-335.

6. Reznikov K.M., Gorbunova N.S., Kolesnichenko P.D., Tverskoy A.V., Kostina D.A., Bashkatova D.A., Nikitina V.A. Search of new pharmaceuticals on the basis of darbepoetin in the treatment of ischemic stroke (review of literature). Research result: pharmacology and clinical pharmacology. 2017; 3(1): 125-136. DOI: 10.18413/2500-235X-2017-3-1-125-136.

7. Peresypkina A.A. Correction of ischemic optic neuropathy in rats by carbamylated darbepoetin. Research Result: Pharmacology and Clinical Pharmacology. 2018; 4(1): 43-50. DOI: 10.3897/ rrpharmacology.4.25262.

8. KDIGO Clinical Practice Guideline for Acute Kidney Injury Kidney International supplements. 2012; 2(1).

9. Banaei S., Ahmadiasl N., Alihemmati A. Comparison of the Protective Effects of Erythropoietin and Melatonin on Renal Ischemia-Reperfusion Injury. Trauma Monthly. 2016; 21(3): e23005. DOI:10.5812/traumamon.23005.

10. Mofidi A., Bader A., Pavlica S. The use of erythropoietin and its derivatives to treat spinal cord injury. Mini Rev. Med. Chem. 2011; 11(9): 763-770.

11. Zhuchenko M.A., Serebryakova M.V., Seregin Yu.A., Cherepushkin S.A., Lobanova N.V., Klishin A.A., Vologzhannikova A.A., Kazakov A.S., Permyakov S.E. Carbamylated Darbepoetin Alfa: Structure and Properties. Biotechnology. 2017; 33(4): 28-43. DOI: 10.21519/0234-2758-2017-33-4-28-43.

12. Okada T., Sawada T., Kubota K. Asialoerythropoietin has strong renoprotective effects against ischemia-reperfusion injury in a murine model. Transplantation. 2007; 84(4): 504-510.

13. Dolzhikova I.N., Pokrovskii M.V., Dolzhikov A.A. Morfologicheskoe i immunogistohimicheskoe issledovanie pochek pri ishemii i na fone distantnogo i farmakologicheskogo prekondicionirovaniya. Nauchnyj aspekt. 2015; 2(3): 282-308. (In Russ.).

14. Shabelnikova A.S. Correction of ischemic damage to the retina on application of pharmacological preconditioning of recombinant erythropoietin. Research result: pharmacology and clinical pharmacology. 2016; 2(2): 67-90.

15. Shabelnikova A.S., Peresypkina A.A., Gubareva V.O., Levkova E.A., Dolzhikov A.A., Nikolaev S.B., Stepchenko A.A. Pharmacological preconditioning by recombinant erythropoietin as the possibility of increasing the stability of tissue of the retina to reperfusion ischemia in experiment. Research result: pharmacology and clinical pharmacology. 2016; 1(2): 25-29.

16. Moore E.M., Bellomo R., Nichol A.D. Erythropoietin as a novel brain and kidney protective agent. Anaesth Intensive Care. 2011; 39: 356-372.

17. Song Y.R., Lee T., You S.J., Chin H.J., Chae D.W., Lim C., Park K.H., Han S., Kim J.H., Na K.Y. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol. 2009; 30: 253-260